What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Javier Cortes mainly investigates Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Trastuzumab.
His studies in Internal medicine integrate themes in fields like Placebo and Surgery.
His Oncology study combines topics from a wide range of disciplines, such as Taxane, Chemotherapy, Clinical endpoint, Pertuzumab and Triple-negative breast cancer.
The various areas that Javier Cortes examines in his Breast cancer study include Cancer research, Clinical trial, Pathology and Metastasis.
His Metastatic breast cancer study combines topics in areas such as Bevacizumab and Breast disease.
His Trastuzumab research includes themes of Gastroenterology, Receptor, Loading dose and Ejection fraction.
His most cited work include:
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (1664 citations)
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (997 citations)
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (735 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer.
His research is interdisciplinary, bridging the disciplines of Surgery and Internal medicine.
His Oncology research incorporates elements of Taxane, Phases of clinical research, Triple-negative breast cancer and Docetaxel.
His work in Breast cancer covers topics such as Gastroenterology which are related to areas like Neutropenia.
His Metastatic breast cancer research is multidisciplinary, incorporating elements of Anthracycline, Capecitabine, Hazard ratio, Bevacizumab and Pharmacology.
The study of Cancer is intertwined with the study of Tolerability in a number of ways.
He most often published in these fields:
- Internal medicine (74.52%)
- Oncology (65.91%)
- Breast cancer (52.20%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (74.52%)
- Oncology (65.91%)
- Breast cancer (52.20%)
In recent papers he was focusing on the following fields of study:
Javier Cortes spends much of his time researching Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer.
His work deals with themes such as Pembrolizumab, Gemcitabine, Abemaciclib and Interim analysis, which intersect with Oncology.
His work investigates the relationship between Breast cancer and topics such as Clinical trial that intersect with problems in Randomized controlled trial and Bevacizumab.
His biological study spans a wide range of topics, including Phases of clinical research, Gastroenterology, Regimen, Capecitabine and Clinical endpoint.
His Cancer study incorporates themes from Radiation therapy, Proportional hazards model and Prospective cohort study.
His Trastuzumab research is multidisciplinary, relying on both Cancer research and Docetaxel.
Between 2019 and 2021, his most popular works were:
- Pembrolizumab for Early Triple-Negative Breast Cancer. (228 citations)
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer (222 citations)
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. (63 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Oncology, Breast cancer, Trastuzumab and Pembrolizumab.
His works in Triple-negative breast cancer, Chemotherapy, Pertuzumab, Metastatic breast cancer and Hazard ratio are all subjects of inquiry into Internal medicine.
His research in Oncology intersects with topics in Gemcitabine, Letrozole and Early breast cancer.
His Breast cancer study improves the overall literature in Cancer.
His studies deal with areas such as Cancer research and Clinical endpoint as well as Trastuzumab.
The Pembrolizumab study combines topics in areas such as Neutropenia and Disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
